HEALTH

PNG Gerolymatos introduces natural ear wax removal solution

BY Michael Johnsen

NEW YORK PNG Gerolymatos on Tuesday launched its EARinse all-natural ear wax removal solution for preventing excess ear wax and infection into the U.S. market. “For years, consumers eager to remove excess ear wax have relied upon chemical cleansing solutions or ear swabs, which can lead to ear drum damage,” stated Basil Theofanopoulos, managing director, North America, Gerolymatos. “We are pleased to provide U.S. consumers with an all-natural, room-temperature remedy to maintain ear cleanliness and help prevent ear infection.”

Made from pure seawater harvested off the coast of St. Malo, France, EARinse is an all-natural hypertonic saline solution that cleanses the ear canal by dissolving ear wax in a comfortable, room-temperature spray. EARinse’s patented flexible safety applicator is designed to adapt to the shape of the ear, guaranteeing gentle delivery of the product and safeguarding against damaging the ear drum. EARinse’s organic seawater solution mimics the body’s natural chemistry to help balance ear pressure and prevent infection, and can be used safely in combination with other treatments.

EARinse is the second product offered by PNG Gerolymatos in the United States, following the introduction of Breathe Again nasal spray, an all-natural seawater nasal spray in the U.S.

EARinse is available at major retailers nationwide such as Albertson’s, CVS, Duane Reade, Pathmark Supermarkets, Price Chopper, Weis Markets and Walgreens, Gerolymatos reported.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

NAD refers Colotox ad claims to FDA

BY Michael Johnsen

NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Monday referred the advertising claims of Central Coast Nutraceuticals’ regarding “Colotox” to both the Federal Trade Commission and the Food and Drug Administration for further review after Central Coast failed to respond to an NAD inquiry.

According to NAD, Colotox is marketed as a colon cleanser and implies that the product can be used in the prevention of colon cancer.

NAD requested substantiation for express claims, including that  Colotox will help to/with:

  • Remove toxic buildup 
  • Increase your energy levels 
  • Cleanse your entire system 
  • Decrease gas and bloating 
  • Reduce water retention 
  • Detoxify your organs 
  • Give you radiant hair, skin and nails 
  • Bad breath
  • Lose excess weight

Also, that Colotox could be used in relief of thise ailments:

  • Chronic fatigue  
  • Low energy levels  
  • Constipation  
  • Bloating  
  • Bad breath  
  • Detoxify your organs  
  • Excess weight you just can’t seem to lose

NAD also requested substantiation for the implied claims related to colon-cancer prevention, including: 

  • Colon cancer is currently the second leading cancer killer in the United States, with 60,000 Americans expected to die from the disease this year. 
  • “An estimated 150,000 people in America will be diagnosed with colorectal cancer this year, and while progress is being made to prevent and treat the disease, tragically more than 57,000 will die from it
  • “Colon cancer is one of the deadliest diseases to affect Americans”
  • “The Early Show medical correspondent Dr. Emily Senay reports that an average of 57,000 Americans die each year from colon cancer”
  • “When colon cancer is caught late, it is survivable only 8% of the time”

NAD, which made several attempts to contact the advertiser, noted that it was disappointed the advertiser did not respond to the NAD’s inquiry, “especially in light of the strong health-related and weight-loss claims being made in the advertising. Pursuant to its procedures, NAD has referred the matter to the appropriate federal agencies. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Bristol-Myers Squibb splits Mead Johnson into public offering

BY Michael Johnsen

NEW YORK Bristol-Myers Squibb on Wednesday split its Mead Johnson Nutrition Company division, which markets Enfamil, into an initial public offering.

“Today marks important milestones in both our company’s transformation to a BioPharma leader and the launch of Mead Johnson Nutrition Company as a publicly-traded company,” stated James Cornelius, chairman and CEO, Bristol-Myers Squibb and chairman, Mead Johnson Nutrition Company. “Mead Johnson is a unique and powerful brand. We believe that today’s initial public offering of Mead Johnson will allow it to maximize the value of its brand by implementing growth plans and increasing shareholder value, while also providing Bristol-Myers Squibb with a steady source of profits, cash flow and growth,” he said.

“With its own publicly traded equity, Mead Johnson will be better able to accelerate its growth. The offering allows Bristol-Myers Squibb to further strengthen our capital structure as well as increase our focus on the BioPharma business portfolio, fulfilling yet another part of our health care business strategy we announced just over one year ago,” Cornelius added.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?